American BioMed Inc. receives notice of allowance for an additional patent for its stents.THE WOODLANDS, Texas--(BUSINESS WIRE)--Oct. 1, 1996--American BioMed Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB:ABMI ABMI Autologous Bone Marrow Infusion ), of The Woodlands, Tuesday announced that its application for patent filed Dec. 16, 1994, for its Stent for Supporting a Blood Vessel blood vessel n. An elastic tubular channel, such as an artery, a vein, a sinus, or a capillary, through which the blood circulates. blood vessel(s), n the network of muscular tubes that carry blood. , has received a Notice of Allowance from the U.S. Patent and Trademark Office. This is the second patent the company will receive for its dual coil, endless loop design stents. The company expects the patent to be issued within three months. Company President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Steven B. Rash, stated: "The company is obviously very pleased to receive this patent. It demonstrates the company's ingenuity in its ability to create a medical device which we believe is superior in design and performance to any other stent in the industry. The company will continue its focus on the implementation of its strategic plan and will move forward very diligently to bring its stent technology to market, either, on its own or with the support of a strong strategic alliance or industry partner." Industry analysts anticipate very rapid expansion in the world-wide stent market with sales approaching $1.2-billion this year and expected to reach $2-billion by 1998. American BioMed Inc. utilizes state of the art technology to develop, manufacture and market minimally invasive medical, surgical and diagnostic devices which deliver unique advantages through advanced science. Over 25 patents cover its technologies competing in an industry with combined markets estimated at over $10-billion annually. The devices include but are not limited to the OmniCath(r) atherectomy catheter, as well as the company's nine patented FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approved unique all-silicone balloon catheters. These consist of thermodilution, embolectomy embolectomy /em·bo·lec·to·my/ (em?bo-lek´tah-me) surgical removal of an embolus. em·bo·lec·to·my n. Surgical removal of an embolus. embolectomy surgical removal of an embolus. and bi-lumen irrigation irrigation, in agriculture, artificial watering of the land. Although used chiefly in regions with annual rainfall of less than 20 in. (51 cm), it is also used in wetter areas to grow certain crops, e.g., rice. , urinary bladder and angioscopy catheters. The OmniStent(tm) and accompanying stent technology is used to support diseased blood vessels. Other devices such as the company's drug delivery catheters, guidewire microfilter and minimally invasive spinal instruments are also under development. CONTACT: Thomas E. Waite & Associates Inc. Phone 407/324-1606/Fax 407/324-0664 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion